Rapid Micro Biosystems, Inc. (RPID)

NCM – Real vaqt narxi. Valyuta: USD

2.58

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.63

+0.05 (1.94%)

Bozor oldidan: May 13, 2026, 8:06 AM EDT

06.05.2026

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2026 financial results after the market close on Wednesday, May 13, 2026.

14.04.2026

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

13.03.2026

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative margins and ongoing cash burn temper near-term optimism.

12.03.2026

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

12.03.2026

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Reports record fourth quarter 2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% growth compared to 2024 Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026 Samsung Biologics continues to expand Growth Direct deployment across its manufacturing network with a meaningful multi-system order in the first quarter 2026 For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margin percentage of approximately 20% LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

12.03.2026

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Companies deepen partnership to advance automated, integrated microbiology quality control Companies deepen partnership to advance automated, integrated microbiology quality control

10.03.2026

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the KeyBanc Capital Markets Healthcare Forum.

Videolar

No Data

There is no data to display

Press-relizlar

12.03.2026

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

12.03.2026

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Companies deepen partnership to advance automated, integrated microbiology quality control Companies deepen partnership to advance automated, integrated microbiology quality control

10.03.2026

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

12.02.2026

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on February 2, 2026, of an aggregate of 205,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) and non-qualified stock options to purchase an aggregate of 168,000 shares of Common Stock (the “Options”), all as a material inducement to employment for three new employees. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.

Rapid Micro Biosystems, Inc. (RPID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rapid Micro Biosystems, Inc. (RPID)

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Videolar

No Data

Press-relizlar

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Videolar

No Data

Press-relizlar

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Rapid Micro Biosystems, Inc. (RPID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rapid Micro Biosystems, Inc. (RPID)

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Videolar

No Data

Press-relizlar

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Videolar

No Data

Press-relizlar

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)